28.71
Schlusskurs vom Vortag:
$28.62
Offen:
$28.81
24-Stunden-Volumen:
163.27K
Relative Volume:
0.42
Marktkapitalisierung:
$1.47B
Einnahmen:
$413.05M
Nettoeinkommen (Verlust:
$-27.67M
KGV:
-51.18
EPS:
-0.561
Netto-Cashflow:
$-30.75M
1W Leistung:
+1.84%
1M Leistung:
-1.67%
6M Leistung:
-21.71%
1J Leistung:
-19.14%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings Plc Adr
|
28.82 | 1.46B | 413.05M | -27.67M | -30.75M | -0.561 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.39 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
615.39 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
898.11 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.95 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
153.71 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-07 | Hochstufung | UBS | Sell → Buy |
| 2025-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-18 | Fortgesetzt | Guggenheim | Neutral |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
IMCR Stock Price, Quote & Chart | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewswire Inc.
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Wall Street analysts think Immunocore (IMCR) could surge 111.53%: Read this before placing a bet - MSN
69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR) - Stock Titan
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - TradingView
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet - Yahoo Finance
Immunocore Holdings (NASDAQ: IMCR) plans 65,000 ADR cashless sale - Stock Titan
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - TradingView
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - TradingView
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - TradingView
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention - TradingView
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment - Stock Titan
Immunocore Holdings stock (GB00BL963Z95): Recent price dip amid biotech trends - AD HOC NEWS
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - TradingView
Mizuho cuts Immunocore stock price target to $34 on trimmed revenue - Investing.com
IMCR SEC FilingsImmunocore Holdings Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Hussman Strategic Advisors Inc. Purchases Shares of 42,000 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Immunocore (IMCR) upgraded to strong buy: Here's why - MSN
Q1 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
Massachusetts Financial Services Co. MA Trims Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore (NASDAQ: IMCR) outlines 10 resolutions for 2026 hybrid AGM - Stock Titan
H.C. Wainwright reiterates Immunocore stock rating citing KIMMTRAK penetration - Investing.com
Immunocore Details KIMMTRAK Growth, TCR Platform and Key Readouts at Needham Conference - Yahoo Finance
Immunocore Holdings Plc (NASDAQ: IMCR) plans same‑day cashless sale of 25,000 ADRs - Stock Titan
Immunocore Holdings stock: What you need to know for smart investing now - AD HOC NEWS
Immunocore Holdings plc (IMCR) stock price, news, quote and history - uk.finance.yahoo.com
Immunocore Holdings stock: Precision Oncology Leader with ImmTAC Innovation - AD HOC NEWS
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Short Interest Down 15.4% in March - MarketBeat
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):